Log In
BCIQ
Print this Print this
 

AMG 330

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionBispecific T cell engager (BiTE) against CD33 and CD3
Molecular Target CD33 ; CD3
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today